STOCKHOLM, SWEDEN--(Marketwire - July 07, 2009) -
STOCKHOLM - July 7, 2009 - Biovitrum AB (publ) (STO: BVT) has selected The Bank of New York Mellon (NYSE: BK), as the depositary bank for its Level I American depositary receipt (ADR) program. Each Biovitrum ADR represents one common share and trades on the over-the-counter market. The common shares trade on the Stockholm OMX Nordic Exchange under the symbol “BVT.”
“We are very happy with the agreement with The Bank of New York Mellon as it has a strong and proven track record,” said Martin Nicklasson, CEO of Biovitrum. “We wish to optimize U.S. investor access to our share, and we believe the Bank has the resources and expertise necessary to help us achieve that goal.”
“We look forward to helping Biovitrum unlock the potential of the U.S. capital markets,” said Michael Cole-Fontayn, chief executive officer of The Bank of New York Mellon’s Depositary Receipt Division. “As the world’s leading depositary, The Bank of New York Mellon will utilize its resources to develop a long and mutually beneficial partnership with Biovitrum and its investors.”
About Biovitrum Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions. Using its expertise and experience Biovitrum takes scientific innovation to patients with significant unmet medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company has revenues of approximately SEK 1.2 billion and around 400 employees. The company head office is located in Sweden and it is listed on the Stockholm OMX Nordic Exchange. For more information please visit www.biovitrum.com
About Bank of New York Mellon The Bank of New York Mellon acts as depositary for more than 2,100 American and global depositary receipt programs, acting in partnership with leading companies from 67 countries. With an unrivalled commitment to helping securities issuers succeed in the world’s rapidly evolving financial markets, the Company delivers the industry’s most comprehensive suite of integrated depositary receipt, corporate trust and stock transfer services. Additional information is available at www.bnymellon.com/dr.
Biovitrum AB (publ) may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was provided for public release on July 7, 2009 at 3.00 p.m. CET.
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
For more information please contact:
Biovitrum
Martin Nicklasson, CEO
Phone: +46 8 697 2545
Göran Arvidson, CFO
Cell phone: +46 70 633 30 42
Erik Kinnman, VP Investor Relations
Cell phone: +46 73 422 15 40
Email Contact
